Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

IGF-1

Insulin-like Growth Factor 1, Somatomedin C

Quick Stats
Studies 92
Trials 100
Score 2
2025 pubmed

Impact of dietary Phyllanthus emblica on growth, immunity, antioxidant capacity, and Fusarium oxysporum resistance in red tilapia.

Mathew. Roshmon Thomas RT; Alkhamis. Yousef Ahmed YA; Alsaqufi. Ahmed Saud AS; Mansour. Abdallah Tageldein AT; Ghazzawy. Hesham S HS; Ganesan. Nagarajan N; Eissa. Moaheda E H MEH; Abdul Kari. Zulhisyam Z; El-Haroun. Ehab E; Abass. Kasim Sakran KS; Rinthong. Prasob-Orn PO; Eissa. El-Sayed Hemdan EH

Key Findings

  • 5 g of amla powder per kg of feed gave the best growth performance and raised IGF‑1 gene expression in red tilapia.
  • 20 g/kg feed improved immune‑related genes and antioxidant enzymes more than the lower dose.
  • All amla‑supplemented groups showed better liver health markers, lower blood lipids, and stronger antioxidant enzyme activity.

Practical Outcomes

  • For biohackers, the take‑away is that a modest amount of amla (about 0.5% of the diet) may help stimulate IGF‑1 pathways, at least in fish, while a higher dose may be better for immune support. Human effects are unproven, so any use should start with low doses and monitor health markers.

Summary

Adding a small amount of the fruit powder Phyllanthus emblica (also called amla) to tilapia feed helped the fish grow faster and increased the activity of the growth hormone IGF‑1 gene. A higher amount of the powder didn’t boost growth as much but did improve the fish’s immune system and antioxidant defenses. The study shows that the dose matters: low‑dose for growth, higher‑dose for health protection.

Abstract

Identifying natural growth-promoting agents and implementing environmentally sustainable methodologies are paramount strategies for enhancing the performance and welfare of aquatic fish farms. Phyllanthus emblica (PE) possesses a broad spectrum of bioactive properties, including antioxidant, antiviral, antimicrobial, and immunomodulatory effects. Hence, this study aimed to investigate the beneficial effects of PE dietary supplementation on the growth, immunity, redox homeostasis, organ histology, gene transcripts, and disease resistance of Red Tilapia against Fusarium oxysporum. A total of 240 fish (25.0 ± 3.0 g) were randomly distributed among 12 ponds, with 20 fish per pond. The fish were fed a basal diet supplemented with 0 (PE0), 5 (PE5), 10 (PE10), or 20 g of PE powder per kg of diet for 70 days. Following the trial, a challenge test was carried out. The PE5 group achieved significantly greater body weight, weight gain, specific growth rate (SGR) and digestive enzymes (lipase and amylases) than the PE20 group (p < 0.05). However, the PE5 group recorded the best feed conversion ratio compared to the other groups (p < 0.05). All PE-supplemented groups exhibited lower muscle lipid content and higher ash content (p < 0.05). PE-fortified groups displayed substantially lower levels of liver enzymes (AST, ALT, and ALP), creatinine, glucose, and lipid profile (cholesterol, triglycerides) compared to the PE0 group (p < 0.05). PE-fortified diets significantly enhanced the fish's antioxidant enzyme activities (SOD, CAT, and GPx), immunological parameters (p < 0.05) for phagocytic activity, phagocytic index, and WBCs) and preserved the intestinal and hepatic tissues. The supplementation of 5 g PE/kg in Red Tilapia significantly enhanced the gene expression of growth genes (GH and IGF-1). In contrast, the group supplemented with 20 g PE/kg showed superior results for immune-related genes (including CC chemokines and interleukin-8) and antioxidant enzymes (SOD and GPx) (p < 0.05). Overall, the inclusion of 5 g/kg PE optimized growth performance in Red Tilapia, while the inclusion of 20 g/kg resulted in superior immune and antioxidant capabilities. These results highlight PE's dual potential to enhance growth and boost health, confirming its promise as a natural feed additive for sustainable Tilapia aquaculture.

Study Information

Provider

pubmed

Year

2025

Date

2025-11-27T00:00:00.000Z

DOI

10.1038/s41598-025-26553-5

References

65